Regulating of growth hormone sensitivity by sex steroids: implications for therapy
- PMID: 16809927
- DOI: 10.1159/000094314
Regulating of growth hormone sensitivity by sex steroids: implications for therapy
Abstract
Growth hormone (GH) is an important regulator of body composition, reducing body fat by stimulating fat oxidation and enhancing lean body mass by stimulating protein accretion. The emergence of differences in body composition between the sexes during puberty suggests sex steroids modulate the action of GH. Work from our laboratory have investigated the influence of estrogens and androgens on the metabolic actions of GH in human adults. The liver is an important site of physiological interaction as it is a sex steroid responsive organ and a major target of GH action. Estrogen, when administered orally impairs the GH-regulated endocrine and metabolic function of the liver via a first-pass effect. It reduces circulating IGF-I, fat oxidation and protein synthesis, contributing to a loss of lean and a gain of fat mass. These effects occur in normal and in GH-deficient women and are avoided by transdermal administration of physiological doses of estrogen. In contrast, studies in hypopituitary men indicate that testosterone enhances the metabolic effects of GH. Testosterone alone stimulates fat oxidation and protein synthesis, both of which are enhanced by GH. Studies in GH deficiency adults have consistently reported women to be less sensitive to GH than men. In summary, estrogens and androgens exert divergent effects on the action of GH. The results provide an explanation for sexual dimorphism in body composition in adults and the gender-related response to GH replacement in hypopituitary subjects. In the management of hypopituitarism, estrogens should be administered by the parenteral route in women and testosterone be replaced in men to optimize the benefits of GH replacement.
Similar articles
-
Modulation of growth hormone action by sex steroids.Clin Endocrinol (Oxf). 2006 Oct;65(4):413-22. doi: 10.1111/j.1365-2265.2006.02676.x. Clin Endocrinol (Oxf). 2006. PMID: 16984231 Review.
-
Sex steroids and the GH axis: Implications for the management of hypopituitarism.Best Pract Res Clin Endocrinol Metab. 2017 Feb;31(1):59-69. doi: 10.1016/j.beem.2017.03.003. Epub 2017 Mar 14. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28477733 Review.
-
Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty.Horm Res. 1996;45(1-2):74-80. doi: 10.1159/000184763. Horm Res. 1996. PMID: 8742123 Review.
-
Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.J Clin Endocrinol Metab. 2000 Mar;85(3):1121-5. doi: 10.1210/jcem.85.3.6463. J Clin Endocrinol Metab. 2000. PMID: 10720049 Clinical Trial.
-
The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.J Clin Invest. 1998 Sep 1;102(5):1035-40. doi: 10.1172/JCI2773. J Clin Invest. 1998. PMID: 9727072 Free PMC article. Clinical Trial.
Cited by
-
The acromegaly lipodystrophy.Front Endocrinol (Lausanne). 2022 Sep 13;13:933039. doi: 10.3389/fendo.2022.933039. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36176462 Free PMC article.
-
Variation of the baseline characteristics and treatment parameters over time: an analysis of 15 years of growth hormone replacement in adults in the German KIMS database.Pituitary. 2012 Dec;15 Suppl 1:S72-80. doi: 10.1007/s11102-012-0410-z. Pituitary. 2012. PMID: 22829164
-
Normal levels of serum IGF-I: determinants and validity of current reference ranges.Pituitary. 2007;10(2):129-33. doi: 10.1007/s11102-007-0035-9. Pituitary. 2007. PMID: 17487588 Review.
-
Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.J Clin Endocrinol Metab. 2015 Aug;100(8):2946-55. doi: 10.1210/jc.2015-1917. Epub 2015 Jun 2. J Clin Endocrinol Metab. 2015. PMID: 26037515 Free PMC article. Clinical Trial.
-
IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.Pituitary. 2015 Dec;18(6):808-19. doi: 10.1007/s11102-015-0657-2. Pituitary. 2015. PMID: 25907335 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources